Staff Profile

Qualifications:

Postgraduate Certificate in Clinical research 2012

PhD 1999
FIMLS (in clinical chemistry) 1988
BSc Hons (Biochemistry 1983

Current position:

Newcastle Cancer Centre (NCC) Project Coordinator Jul 2013-present

Previous Positions:

Tissue Banking and Trials Coordinator- Sir Bobby Robson Cancer Trials Centre Oct 2010-Jun 2013

Clinical Trials Coordinator/Lab Supervisor- Sir Bobby Robson Cancer Trials Centre  Apr 2010-Sep 2010  

Senior Research Associate - Leukaemia Research Group,  Newcastle UniversityJan  2002-  Mar 2010

Research Associate - Leukaemia Research Group,  Newcastle University Apr1990-Dec 2001

Medical Laboratory Scientific Officer Oct 1983 - Mar 1990

Current research:

Management of  translational research studies in patients with solid tumours

Previous research:

Factors influencing the metabolism and efficacy of thiopurine drugs
Cell cycle de-regulation in acute lymphoblastic leukaemia

Drug resistance mechanisms in acute lymphoblastic leukaemia

• Greystoke A, Hogarth L, Patterson M, Williams I, Ness T, Georgiadis K, Bolt L, Bettison I, Turner D, Jamieson D, Simmons T, Hughes A, Jaedicke K, Gardiner J, Mulvenna P, Leaning D, Bradshaw A, Butler R, Black F. The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier.
• Davies C, Hogarth LA, Mackenzie KL, Hall AG, Lock RB. p21^WAF1 modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia. Cell Cycle 2015, 14(22), 3602-3612.
• Deva S, Baird RD, Cresti N, Garcia-Corbacho J, Hogarth L, Frenkel EP, Kawaguchi K, Arimura A, Donaldson K, Posner J, Sarker D, Jodrell DI, Plummer R, Spicer JF. Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases. In: ASCO Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
• Coulthard SA, Redfern CPF, Vikingsson S, Lindqvist-Appell M, Skoglund K, Jakobsen-Falk I, Hall AG, Taylor GA, Hogarth LA. Increased Sensitivity to Thiopurines in Methylthioadenosine Phosphorylase-Deleted Cancers. Molecular Cancer Therapeutics 2011, 10(3), 495-504.
• Davies C, Hogarth LA, Dietrich PA, Bachmann PS, Mackenzie KL, Hall AG, Lock RB. p53-independent Epigenetic Repression of the p21^WAF1 Gene in T-cell Acute Lymphoblastic Leukemia. Journal of Biological Chemistry 2011, 286(43), 37639-37650.
• Irving JAE, Bloodworth LC, Bown NP, Case MC, Hogarth LA, Hall AG. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Research 2005, 65(8), 3053-3058.
• Coulthard SA, Hogarth LA. The thiopurines: An update. Investigational New Drugs 2005, 23(6), 523-532.
• Coulthard SA, Matheson EC, Hall AG, Hogarth LA. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. In: Joint 11th International and 9th European Symposium on Purines and Pyrimidines. 2004, Man Egmond Aan Zee, Netherlands: Nucleosides, Nucleotides and Nucleic Acids: Taylor & Francis Inc.
• Coulthard, S.A., Hogarth, L.A., Little, M.A., Matheson, E., Redfern, C.P.F., Minto, C.L.J., Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Molecular Pharmacology 2002, 62(1), 102-109.
• Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999, 93(8), 2671-2678.
• Hogarth LA, English M, Price L, Wyllie R, Pearson ADJ, Hall AG. The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine. Cancer Chemotherapy and Pharmacology 1996, 37(5), 479-485.
• Wyatt N, Hogarth L, Turner D, Patterson M, Jamieson D, Black F, Hutton C, Mulvenna P, Simmons T, Bradshaw A, Kolenda C, Parker C, Martin-Ruiz C, Greystoke A. Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). In: IASLC 17th World Conference on Lung Cancer. 2016, Vienna, Austria: Elsevier.